FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort

Jeff Johnson, Michael Choi, Farnaz Dadmanesh, Bingchen Han, Ying Qu, Yi Yu-Rice, Xiao Zhang, Sanjay Bagaria, Clive Taylor, Armando E. Giuliano, Farin Amersi, Xiaojiang Cui

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Breast cancers arising in the setting of the hereditary breast cancer genes BRCA1 and BRCA2 are most commonly classified as basal-like breast cancer (BLBC) or luminal breast cancer, respectively. BLBC is an aggressive subtype of breast cancer associated with liver and lung metastases and poorer prognosis than other subtypes and for which chemotherapy is the only systemic therapy. Multiple immunohistochemical markers are used to identify the basal-like subtype, including the absence of estrogen receptor alpha, progesterone receptor, and human epidermal growth factor receptor 2. Forkhead box C1 (FOXC1) has been identified as a specific marker expressed in BLBC in general breast cancer cohorts. We examined an institutional cohort of breast cancer patients with germline BRCA1 (n=46) and BRCA2 (n=35) mutations and found that FOXC1 expression on immunohistochemical staining is associated with BRCA1 vs BRCA2 mutations [30/46 vs. 6/35]. In BRCA1 mutant tumors, FOXC1 was expressed in 28/31 BLBC tumors and 2/13 non-BLBC tumors, In BRCA2 mutant tumors, FOXC1 was expressed in 5/5 BLBC tumors and 1/30 non-BLBC tumors. In cell culture models of BRCA1-mutant breast cancer, FOXC1 is associated with increased proliferation and may serve as a marker for sensitivity to PARP-inhibitor therapy with olaparib.

Original languageEnglish (US)
Pages (from-to)75729-75738
Number of pages10
JournalOncotarget
Volume7
Issue number46
DOIs
StatePublished - 2016

Fingerprint

Breast Neoplasms
Mutation
Estrogen Receptor alpha
Neoplasm Genes
Progesterone Receptors
Neoplasms
Cell Culture Techniques
Staining and Labeling
Neoplasm Metastasis
Drug Therapy
Lung

Keywords

  • Basal-like breast cancer
  • BRCA
  • FOXC1
  • Immunohistochemistry
  • PARP inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Johnson, J., Choi, M., Dadmanesh, F., Han, B., Qu, Y., Yu-Rice, Y., ... Cui, X. (2016). FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. Oncotarget, 7(46), 75729-75738. https://doi.org/10.18632/oncotarget.12370

FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. / Johnson, Jeff; Choi, Michael; Dadmanesh, Farnaz; Han, Bingchen; Qu, Ying; Yu-Rice, Yi; Zhang, Xiao; Bagaria, Sanjay; Taylor, Clive; Giuliano, Armando E.; Amersi, Farin; Cui, Xiaojiang.

In: Oncotarget, Vol. 7, No. 46, 2016, p. 75729-75738.

Research output: Contribution to journalArticle

Johnson, J, Choi, M, Dadmanesh, F, Han, B, Qu, Y, Yu-Rice, Y, Zhang, X, Bagaria, S, Taylor, C, Giuliano, AE, Amersi, F & Cui, X 2016, 'FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort', Oncotarget, vol. 7, no. 46, pp. 75729-75738. https://doi.org/10.18632/oncotarget.12370
Johnson J, Choi M, Dadmanesh F, Han B, Qu Y, Yu-Rice Y et al. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. Oncotarget. 2016;7(46):75729-75738. https://doi.org/10.18632/oncotarget.12370
Johnson, Jeff ; Choi, Michael ; Dadmanesh, Farnaz ; Han, Bingchen ; Qu, Ying ; Yu-Rice, Yi ; Zhang, Xiao ; Bagaria, Sanjay ; Taylor, Clive ; Giuliano, Armando E. ; Amersi, Farin ; Cui, Xiaojiang. / FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. In: Oncotarget. 2016 ; Vol. 7, No. 46. pp. 75729-75738.
@article{a7eb13b6654542009a2446877d47e8b7,
title = "FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort",
abstract = "Breast cancers arising in the setting of the hereditary breast cancer genes BRCA1 and BRCA2 are most commonly classified as basal-like breast cancer (BLBC) or luminal breast cancer, respectively. BLBC is an aggressive subtype of breast cancer associated with liver and lung metastases and poorer prognosis than other subtypes and for which chemotherapy is the only systemic therapy. Multiple immunohistochemical markers are used to identify the basal-like subtype, including the absence of estrogen receptor alpha, progesterone receptor, and human epidermal growth factor receptor 2. Forkhead box C1 (FOXC1) has been identified as a specific marker expressed in BLBC in general breast cancer cohorts. We examined an institutional cohort of breast cancer patients with germline BRCA1 (n=46) and BRCA2 (n=35) mutations and found that FOXC1 expression on immunohistochemical staining is associated with BRCA1 vs BRCA2 mutations [30/46 vs. 6/35]. In BRCA1 mutant tumors, FOXC1 was expressed in 28/31 BLBC tumors and 2/13 non-BLBC tumors, In BRCA2 mutant tumors, FOXC1 was expressed in 5/5 BLBC tumors and 1/30 non-BLBC tumors. In cell culture models of BRCA1-mutant breast cancer, FOXC1 is associated with increased proliferation and may serve as a marker for sensitivity to PARP-inhibitor therapy with olaparib.",
keywords = "Basal-like breast cancer, BRCA, FOXC1, Immunohistochemistry, PARP inhibitor",
author = "Jeff Johnson and Michael Choi and Farnaz Dadmanesh and Bingchen Han and Ying Qu and Yi Yu-Rice and Xiao Zhang and Sanjay Bagaria and Clive Taylor and Giuliano, {Armando E.} and Farin Amersi and Xiaojiang Cui",
year = "2016",
doi = "10.18632/oncotarget.12370",
language = "English (US)",
volume = "7",
pages = "75729--75738",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "46",

}

TY - JOUR

T1 - FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort

AU - Johnson, Jeff

AU - Choi, Michael

AU - Dadmanesh, Farnaz

AU - Han, Bingchen

AU - Qu, Ying

AU - Yu-Rice, Yi

AU - Zhang, Xiao

AU - Bagaria, Sanjay

AU - Taylor, Clive

AU - Giuliano, Armando E.

AU - Amersi, Farin

AU - Cui, Xiaojiang

PY - 2016

Y1 - 2016

N2 - Breast cancers arising in the setting of the hereditary breast cancer genes BRCA1 and BRCA2 are most commonly classified as basal-like breast cancer (BLBC) or luminal breast cancer, respectively. BLBC is an aggressive subtype of breast cancer associated with liver and lung metastases and poorer prognosis than other subtypes and for which chemotherapy is the only systemic therapy. Multiple immunohistochemical markers are used to identify the basal-like subtype, including the absence of estrogen receptor alpha, progesterone receptor, and human epidermal growth factor receptor 2. Forkhead box C1 (FOXC1) has been identified as a specific marker expressed in BLBC in general breast cancer cohorts. We examined an institutional cohort of breast cancer patients with germline BRCA1 (n=46) and BRCA2 (n=35) mutations and found that FOXC1 expression on immunohistochemical staining is associated with BRCA1 vs BRCA2 mutations [30/46 vs. 6/35]. In BRCA1 mutant tumors, FOXC1 was expressed in 28/31 BLBC tumors and 2/13 non-BLBC tumors, In BRCA2 mutant tumors, FOXC1 was expressed in 5/5 BLBC tumors and 1/30 non-BLBC tumors. In cell culture models of BRCA1-mutant breast cancer, FOXC1 is associated with increased proliferation and may serve as a marker for sensitivity to PARP-inhibitor therapy with olaparib.

AB - Breast cancers arising in the setting of the hereditary breast cancer genes BRCA1 and BRCA2 are most commonly classified as basal-like breast cancer (BLBC) or luminal breast cancer, respectively. BLBC is an aggressive subtype of breast cancer associated with liver and lung metastases and poorer prognosis than other subtypes and for which chemotherapy is the only systemic therapy. Multiple immunohistochemical markers are used to identify the basal-like subtype, including the absence of estrogen receptor alpha, progesterone receptor, and human epidermal growth factor receptor 2. Forkhead box C1 (FOXC1) has been identified as a specific marker expressed in BLBC in general breast cancer cohorts. We examined an institutional cohort of breast cancer patients with germline BRCA1 (n=46) and BRCA2 (n=35) mutations and found that FOXC1 expression on immunohistochemical staining is associated with BRCA1 vs BRCA2 mutations [30/46 vs. 6/35]. In BRCA1 mutant tumors, FOXC1 was expressed in 28/31 BLBC tumors and 2/13 non-BLBC tumors, In BRCA2 mutant tumors, FOXC1 was expressed in 5/5 BLBC tumors and 1/30 non-BLBC tumors. In cell culture models of BRCA1-mutant breast cancer, FOXC1 is associated with increased proliferation and may serve as a marker for sensitivity to PARP-inhibitor therapy with olaparib.

KW - Basal-like breast cancer

KW - BRCA

KW - FOXC1

KW - Immunohistochemistry

KW - PARP inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84996629618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996629618&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12370

DO - 10.18632/oncotarget.12370

M3 - Article

C2 - 27708239

AN - SCOPUS:84996629618

VL - 7

SP - 75729

EP - 75738

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 46

ER -